FeesSafety
Pluang+

TIM S.A. Q3 revenue beats but EPS misses; growth slows amid Brazil's tough market conditions

Company Fundamentals
13 Nov 2026, 11:31 WIB
Seeking Alpha
View Source
Bearish
TIM S.A. Q3 revenue beats but EPS misses; growth slows amid Brazil's tough market conditions

TIM S.A. reported better-than-expected revenue for Q3 but earnings per share (EPS) fell short of forecasts. Growth in the postpaid segment slowed and average revenue per user (ARPU) declined, reflecting ongoing competitive and macroeconomic challenges in Brazil. Operational efficiencies from recent acquisitions helped, but sustainability is uncertain as synergy benefits fade. The stock is fairly valued given sector difficulties, with no immediate catalysts and risks from potential corporate moves and market share losses.

TIM S.A. Q3 results provide context for readers following the company. As of Nov 13, 2026 16:21 WIB, among 150 priced Technology-sector US stocks tradable on Pluang, 63 rose and 71 fell today. Notable movers include EXFY at USD 1.90 with a 1-day change of +2.15% and a typical hold time on Pluang of 42 days, BTDR at USD 6.00 down 2.12% with Pluang order activity showing 11% Sell / 89% Buy, and AVGO at USD 356.82 down 2.07% with a typical hold time of 83 days and Pluang order activity of 39% Sell / 61% Buy.

More News

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...

Bullish
56 minutes ago
PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...

Company Fundamentals
Bullish
2 hours ago
Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...

Company Fundamentals
Neutral
2 hours ago
Shandong-South Korea Economic Conference opens with 23 new cooperation projects signed in Yantai.

Shandong-South Korea Economic Conference opens with 23 new cooperation projects signed in Yantai.

The 9th Shandong-South Korea Economic and Trade Cooperation Conference and Yantai South Korea Week began on November 6 in Yantai, Shandong Province, highlighting strong economic ties between Shandong and South Korea. Over 150 enterprises participated...

Bullish
3 hours ago
DATA.BET partners with Sportradar to supply esports betting data for 1,800+ tournaments globally.

DATA.BET partners with Sportradar to supply esports betting data for 1,800+ tournaments globally.

DATA.BET has signed a partnership deal with Sportradar to provide esports data and betting tools covering over 1,800 tournaments and 94,000 matches annually across more than 60 markets. This collaboration enhances Sportradar's esports offerings with ...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App